Belite Bio, Inc
BLTE Nasdaq Pharmaceutical Preparations Financials FY2020–FY2025
- Today
- 2.3%
- Previous close
- $154.19
- Market cap
- $5.3B
- P/E
- —
- Day range
-
$152.99 $159.49
- 52-week range
-
$105.76 $193.61
Last close · Nov 9, 2026
$157.69
+$44.50 (+39.31%) past year
Key numbers
Key numbers, fiscal 2025
Revenue and margins
Revenue and margins
Revenue
Margins, % of revenue
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Net income
Net income and earnings per share
Loss periods are shown in red.
KIRA summarises the numbers
-
Belite Bio, Inc lost $77.6M in fiscal 2025.
Net income
Diluted EPS
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Cash flow
Cash flow
Cash from operations minus capital spending.
KIRA summarises the numbers
-
Free cash flow was −$37.1M in fiscal 2025.
At that burn of $37.1M a year, its $353M of cash and short-term investments would last about 9.5 years.
Free cash flow
Cash from operations vs capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends and buybacks
Dividends, buybacks and share count
Dividends and buybacks
Diluted shares outstanding (annual)
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Insider trades
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
-
In the last 12 months, insiders sold $40.6M of shares on the open market and bought none.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$40.6M
5 insiders
Of sales under plans
93%
$37.8M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Hendrik Peter SchollChief Medical Officer | Sold plan | 500 | $165.32 | $0.1M | Form 4 |
| Sep 8, 2026 | Yu-Hsin LinChief Executive Officer, Director | Sold plan | 26,000 | $196.56 | $5.1M | Form 4 |
| Sep 8, 2026 | Hao-Yuan ChuangChief Financial Officer, Director | Sold plan | 17,962 | $196.42 | $3.5M | Form 4 |
| Sep 4, 2026 | Hao-Yuan ChuangChief Financial Officer, Director | Sold plan | 49,433 | $187.63 | $9.3M | Form 4 |
| Sep 4, 2026 | Yu-Hsin LinChief Executive Officer, Director | Sold plan | 74,435 | $187.71 | $14.0M | Form 4 |
| Aug 12, 2026 | Hao-Yuan ChuangChief Financial Officer, Director | Sold plan | 367 | $180.35 | $0.1M | Form 4 |
| Aug 12, 2026 | Yu-Hsin LinChief Executive Officer, Director | Sold plan | 365 | $180.35 | $0.1M | Form 4 |
| Jun 18, 2026 | Hendrik Peter SchollChief Medical Officer | Sold | 10,000 | $145.24 | $1.5M | Form 4 |
| Jun 16, 2026 | Hendrik Peter SchollChief Medical Officer | Sold | 10,000 | $140.57 | $1.4M | Form 4 |
| May 7, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 666 | $153.21 | $0.1M | Form 4 |
| May 6, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $153.84 | $0.2M | Form 4 |
| May 5, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $155.50 | $0.2M | Form 4 |
| May 4, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $155.64 | $0.2M | Form 4 |
| May 1, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $155.78 | $0.2M | Form 4 |
| Apr 30, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $156.97 | $0.2M | Form 4 |
| Apr 29, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $155.82 | $0.2M | Form 4 |
| Apr 28, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $159.16 | $0.2M | Form 4 |
| Apr 27, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $162.64 | $0.2M | Form 4 |
| Apr 24, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $159.56 | $0.2M | Form 4 |
| Apr 23, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $166.28 | $0.2M | Form 4 |
| Apr 22, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $170.39 | $0.2M | Form 4 |
| Apr 21, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $166.00 | $0.2M | Form 4 |
| Apr 20, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $163.60 | $0.2M | Form 4 |
| Apr 17, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $161.63 | $0.2M | Form 4 |
| Apr 16, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $160.38 | $0.2M | Form 4 |
| Apr 15, 2026 | Nathan L. MataChief Scientific Officer | Sold plan | 1,000 | $168.30 | $0.2M | Form 4 |
| Apr 9, 2026 | Yu-Hsin LinChief Executive Officer, Director | Sold plan | 9,200 | $181.45 | $1.7M | Form 4 |
| Apr 9, 2026 | Wan-Shan ChenDirector | Sold plan | 1,100 | $180.43 | $0.2M | Form 4 |
| Apr 9, 2026 | Hao-Yuan ChuangChief Financial Officer, Director | Sold plan | 6,200 | $181.50 | $1.1M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Balance sheet
Balance sheet
Cash, debt and the ratios that show how comfortably Belite Bio, Inc can carry it.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $17.3M | $42.1M | $88.2M | $36.2M | $353M |
| Interest coverage | — | −801.3x | −1,266.7x | −1,999.8x | −42,104.0x |
| Current ratio | 10.7x | 20.3x | 24.8x | 24.3x | 50.0x |
| Quick ratio | 10.7x | 20.3x | 24.8x | 24.3x | 50.0x |
| Total assets | $18.3M | $44.3M | $94.6M | $152M | $781M |
| Total liabilities | $1.6M | $2.8M | $4.2M | $6.3M | $10.1M |
| Shareholders' equity | −$15.1M | $41.5M | $90.4M | $146M | $770M |
| Net debt (− = net cash) | — | — | — | — | — |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Returns on capital
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on capital, equity and assets (annual)
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
F-score
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| F-score | — / 4 | — / 6 | — / 6 | — / 6 | — / 6 |
| Accruals ratio | −11.9% | −3.8% | −2.6% | −5.6% | −8.7% |
| Altman Z'' | −12.47 | 16.87 | 23.82 | 26.27 | 82.91 |
| Net income is positive | ✕ | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✕ | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — | — | — |
| Current ratio rose | — | ✓ | ✓ | ✕ | ✓ |
| Share count didn't rise | ✕ | ✕ | ✕ | ✕ | ✕ |
| Gross margin rose | — | — | — | — | — |
| Revenue rose relative to assets | — | — | — | — | — |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
All figures
6 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Research and development | $3.7M | $7.4M | $8.9M | $24.8M | $29.9M | $45.4M |
| Operating income | −$5.7M | −$9.8M | −$12.8M | −$31.7M | −$40.0M | −$84.2M |
| Interest expense | $0.0M | — | $0.0M | $0.0M | $0.0M | $0.0M |
| Pretax income | −$5.8M | −$9.7M | −$12.6M | −$31.6M | −$36.1M | −$77.6M |
| Income tax | $0.0M | — | — | $0.0M | $0.0M | $0.0M |
| Net income | −$5.8M | −$9.7M | −$12.6M | −$31.6M | −$36.1M | −$77.6M |
| Net income to common | −$5.8M | −$9.7M | −$12.6M | −$31.6M | −$36.1M | −$77.6M |
| Diluted EPS | −$0.65 | −$1.01 | −$0.63 | −$1.19 | −$1.18 | −$2.31 |
| Diluted shares | 0.01B | 0.01B | 0.02B | 0.03B | 0.03B | 0.03B |
| Cash flow | ||||||
| Cash from operations | −$4.4M | −$7.5M | −$11.5M | −$29.8M | −$29.2M | −$37.0M |
| Capital expenditure | — | $0.1M | $0.4M | $0.1M | $0.1M | $0.1M |
| Free cash flow | — | −$7.5M | −$11.9M | −$29.9M | −$29.4M | −$37.1M |
| Depreciation and amortization | $0.0M | $0.0M | $0.1M | $0.1M | $0.2M | $0.2M |
| Stock-based compensation | $1.4M | $1.5M | $1.5M | $3.8M | $9.0M | $38.9M |
| Balance sheet | ||||||
| Cash and short-term investments | $25.6M | $17.3M | $42.1M | $88.2M | $36.2M | $353M |
| Current assets | — | $17.4M | $42.8M | $89.9M | $147M | $494M |
| Current liabilities | — | $1.6M | $2.1M | $3.6M | $6.1M | $9.9M |
| Property and equipment, net | — | $0.1M | $0.5M | $0.5M | $0.4M | $0.3M |
| Intangible assets | — | — | — | — | $0.0M | $0.0M |
| Total assets | — | $18.3M | $44.3M | $94.6M | $152M | $781M |
| Total liabilities | — | $1.6M | $2.8M | $4.2M | $6.3M | $10.1M |
| Shareholders' equity | −$7.0M | −$15.1M | $41.5M | $90.4M | $146M | $770M |
| Returns | ||||||
| Return on capital employed | — | −58.6% | −30.4% | −34.8% | −27.4% | −10.9% |
| Return on equity | — | — | −95.8% | −48.0% | −30.6% | −16.9% |
| Return on assets | — | −52.7% | −40.4% | −45.5% | −29.3% | −16.6% |
| Return on tangible equity | — | — | −30.5% | −35.0% | −24.8% | −10.1% |
| Growth | ||||||
| Share count change | — | 8.9% | 108.7% | 33.1% | 14.8% | 9.8% |
| Financial health | ||||||
| Interest coverage | −273.5x | — | −801.3x | −1,266.7x | −1,999.8x | −42,104.0x |
| Current ratio | — | 10.7x | 20.3x | 24.8x | 24.3x | 50.0x |
| Quick ratio | — | 10.7x | 20.3x | 24.8x | 24.3x | 50.0x |
| Quality scores | ||||||
| Altman Z'' | — | −12.5 | 16.9 | 23.8 | 26.3 | 82.9 |
| Accruals ratio | — | −11.9% | −3.8% | −2.6% | −5.6% | −8.7% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
News and filings
Latest SEC filings
The original documents every number on this page comes from.
KIRA analysis
KIRA’s summary AI analyst
Hi! I read Belite Bio, Inc’s latest annual report (fiscal 2025). Here is what stands out:
Belite Bio, Inc in 30 seconds
Good So-so Weak
Does it make a profit?
−$77.6M
No. It lost money last year.
How long would its cash last?
9.5 yrs
Comfortably. It burns $37.1M a year and holds $353M, about 9.5 years at that pace.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Sales and profit
1 1 note
- Belite Bio, Inc lost $77.6M in fiscal 2025.
Cash and shareholders
1 2 notes
- Free cash flow was −$37.1M in fiscal 2025. At that burn of $37.1M a year, its $353M of cash and short-term investments would last about 9.5 years.
- In the last 12 months, insiders sold $40.6M of shares on the open market and bought none.
Source: SEC EDGAR XBRL filings (CIK 0001889109). Data updated November 9, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.